Lituânia - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

laboratórios basi-indústria farmacêutica, s.a. - diklofenako natrio druska - injekcinis ar infuzinis tirpalas - 75 mg/3 ml - diclofenac

Lituânia - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

vetpharma animal health, s.l. (ispanija) - injekcinis tirpalas - 1 ml yra: veikliosios (-iųjų) medžiagos (-ų): tilmikozino 300 mg, ketoprofeno 90 mg; - galvijų kvėpavimo takų ligai (brd) su pireksija, sukeltai tilmikozinui jautrių mannheimia haemolytica, gydyti.

União Europeia - lituano - EMA (European Medicines Agency)

astrazeneca ab - roflumilastas - plaučių liga, lėtinė obstrukcinė - vaistai nuo obstrukcinių kvėpavimo takų ligų, - daliresp yra skirtas palaikomajam sunki lėtinė obstrukcinė plaučių liga (lopl) (fit1 po bronchus mažiau nei 50 % prognozuojamų) susijęs su lėtiniu bronchitu sergantiems dažnų paūmėjimų istorija kaip add-on į gydymą bronchus.

União Europeia - lituano - EMA (European Medicines Agency)

astrazeneca ab - roflumilastas - plaučių liga, lėtinė obstrukcinė - vaistai nuo obstrukcinių kvėpavimo takų ligų, - libertek yra skirtas palaikomajam sunki lėtinė obstrukcinė plaučių liga (lopl) (fit1 po bronchus mažiau nei 50 % prognozuojamų) susijęs su lėtiniu bronchitu sergantiems dažnų paūmėjimų istorija kaip add-on į gydymą bronchus.

União Europeia - lituano - EMA (European Medicines Agency)

novartis europharm limited  - indakaterolio maleatas - plaučių liga, lėtinė obstrukcinė - vaistai nuo obstrukcinių kvėpavimo takų ligų, - oslif breezhaler skiriamas palaikomajam bronchodilatatoriui gydyti oro srauto obstrukciją suaugusiems pacientams, sergantiems lėtiniu obstrukcine plaučių liga.

União Europeia - lituano - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromidas - plaučių liga, lėtinė obstrukcinė - vaistai nuo obstrukcinių kvėpavimo takų ligų, - tovanor breezhaler skiriamas kaip palaikomasis bronchodilatatorinis gydymas simptomų palengvinimui suaugusiems pacientams, sergantiems lėtinės obstrukcinės plaučių ligos (lopl).

União Europeia - lituano - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antinavikiniai vaistai - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

União Europeia - lituano - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepino acetatas - epilepsija - antiepileptics, - zebinix skiriamas kaip papildoma terapija suaugusiems, paaugliams ir vaikams, vyresniems nei 6 metų amžiaus, su šoniniu – traukulių priepuolius su ar be antrinės generalizacijos.

União Europeia - lituano - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

União Europeia - lituano - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcinos - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.